Skip to main content

News

You are here

Innovate Biopharmaceuticals Completes License For Late-Stage Celiac Disease Asset From Alba Therapeutics

Monday, February 29, 2016

Innovate Biopharmaceuticals Inc. today announced that the company has completed an agreement to license all of Alba Therapeutics' assets relating to larazotide acetate, a tight junction regulator, progressing toward Phase 3 clinical trials for the treatment of celiac disease.

Larazotide acetate, now named INN-202, is a novel oral peptide that has consistently demonstrated the reduction of clinical symptoms of celiac disease in multiple clinical trials in more than 800 patients with celiac disease. The latest Phase 2b multi-center clinical trial evaluated the efficacy, safety and tolerability of larazotide acetate in 342 patients with celiac disease. Larazotide acetate has the potential to become the first approved medicine to treat celiac disease and has been granted "Fast Track" designation from the FDA.  INN-202 will begin Phase 3 clinical trials in late 2016.

Read the rest of the PR Newswire release